An open label multicentric phase 1 study of selective cyclin dependent kinase inhibitor P276-00 [P-276] in patients with advanced refractory neoplasms
Phase of Trial: Phase I
Latest Information Update: 26 Jan 2013
At a glance
- Drugs P 276 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Piramal Enterprises
- 31 Dec 2008 Planned number of patients changed from 47 to 50 as reported by ClinicalTrials.gov.
- 31 Dec 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 12 Dec 2006 New trial record.